The aim is to evaluate the readiness of antisense oligonucleotide therapy for infants with genetic epilepsy.
Assessment of existing guidelines on antisense oligonucleotides
Evaluation of therapy approaches for genetically diagnosed infants
Review of treatment protocols related to genetic disorders
Identified applicable therapy approaches for genetic epilepsies
Defined treatment protocols based on genetic diagnosis
Highlighted potential gene therapy for infants with epilepsy
Abstract
This study evaluates the proportion of established antisense oligonucleotides (ASO) assessment guidelines that are amenable to ASO therapy approaches for genetically diagnosed infants.